Analysis of Clinical Efficacy and Safety of Ustekinumab in Treatment of Inflammatory Bowel Disease / 胃肠病学
Chinese Journal of Gastroenterology
;
(12): 711-716, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-1016056
ABSTRACT
Background:
The efficacy of ustekinumab (UST) in the treatment of patients with inflammatory bowel disease (IBD) has been affirmed abroad, but its efficacy and safety have not been reported in China due to its short term of use.Aims:
To analyze the clinical efficacy and safety of UST in the treatment of IBD.Methods:
The clinical data of IBD patients treated with UST from November 2020 to June 2022 in the First Affiliated Hospital of Air Force Medical University were analyzed retrospectively.Results:
A total of 46 patients with IBD treated with UST were enrolled, including 41 patients with Crohn’s disease (CD) and 5 patients with ulcerative colitis (UC). At the 8
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Gastroenterology
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS